The Asian Pacific Association for the Study of the Liver [APASL]

Monthly News

APASL STC 2017 in Mongolia

Dear Colleagues,

On behalf of organizing committee of APASL-STC 2017, we would like to invite you to the 6th APASL-STC on HCV and Co-Infections will be held in on June 16-18 at Palace of Independence Conference Center, Ulaanbaatar, Mongolia.

Due to advances made in understanding of HCV and development of many all-oral DAAs in recent past, management strategies of HCV and co-infections are changing rapidly these days. There is growing need to share more information, provide training, and learn more about nature of HCV and co-infections both in the region and at the global level.

New research with respect to patients with mono and co-infections, disease progress, complications, basic science and current guidelines will be discussed with world opinion leaders in the field. The conference will also provide great opportunities to network decision makers, top scientists and hepatologists.

The meeting will be held in Ulaanbaatar, the modern capital of Mongolia, an ancient nomadic empire established by Huns and Chinggis Khaan.

We enthusiastically invite you to submit abstracts and join us in this conference as well as our beautiful country-Mongolia. This conference is jointly organized by Asian Pacific Association for the Study of the Liver and Mongolian Association for the Study of Liver Diseases. We are looking forward to seeing you in Ulaanbaatar.

Sincerely yours,

President of the APASL-STC 2017, Ulaanbaatar, Mongolia

Professor and Chairman

Department of Infectious Diseases.

Mongolian National University of Medical Sciences

President of the Mongolian Association for the Study of Liver Diseases

APASL STC on HCV and Co-Infection

Venue: Palace of Independence

Date: June 16-18, 2017


Online Registration:

Abstract submission:

APASL New Awards

APASL STC 2017 in Nagasaki

APASL STC in Nagasaki has been successfully held.

The organizer would like to express sincere gratitude to all the support for this conference.

Why I chose the prevention of HCC as a theme at NAGASAKI-STC conference?

With the recent development of DAAs therapy for hepatitis C, it is now possible to achieve a high rate of HCV elimination, i.e. SVR, in patients with hepatitis C, as well as nucleic acid analog treatment for the hepatitis B enabled high rate and reliable suppression of HBV proliferation in hepatitis B patients.

However, even if SVR is achieved after treatment with DAAs in patients with hepatitis C, there are some cases where HCC still occurs afterwards, and the existence of HCC with high malignancy of cells, which rapidly increases after SVR, has been a major problem in my recent experience. There are also some cases in which HCC still newly emerges during nucleic acid analog therapy in patients with chronic hepatitis B.

On the other hand, the incidence of HCC cases of Non-B Non-C has increased by 8 times compared to 20 years ago, according to our cohort study of the Kyushu region. In hepatocytes in which the hepatitis virus is absent, abnormalities in lipid metabolism may be involved in HCC development. I think that there may be intersections between the mechanism of HCC development in the patients with SVR after treatment of hepatitis C, the mechanism of HCC development during nucleic acid analogue treatment and the mechanism of HCC development in the patients with Non-B Non-C HCC.

Currently when the hepatitis virus has been eliminated and control has become possible, the most important thing is to further strengthen the suppression of HCC occurrence, and by justification of HCC risk and application in practical clinics, prediction of carcinogenesis. Japanese patients with chronic hepatitis C and B belong to a group with the highest carcinogenic risk in the world. I hope that presenting the results of basic research and clinical research on the prevention of HCC development in NAGASAKI-STC conference and considering future liver disease research will be milestones in this field.

Dec 2016

Hiroshi Yatsuhashi M.D.

President, APASL Single Topic Conference in Nagasaki

Director General, Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center

Professor, Department of Hepatology, Nagasaki University Graduate School of Biomedical Sciences

APASL STC on Prevention of HCC development in Japan

Date: April 10-12, 2017
City: Nagasaki, Japan
President: Dr. Hiroshi Yatsuhashi

APASL STC 2017 in Cairo

Dear Colleagues,

We are delighted and honored to introduce you to the Single topic Conference on HCV (Real Life Experience) of the Asian Pacific Association for the Study of the Liver (APASL) which will be held at Intercontinental City Stars hotel Convention Center, on 6-8 September 2017 in Cairo, Egypt. We will bring together a distinguished faculty of renowned specialists from AsiaPacific and around the world to this conference.

After the two successful liver fibrosis STC meetings in Cairo on 2008 and 2014, the coming congress have been selected to focus on HCV and its remarkable fast progress in the new treatment modalities. Egyptians have the highest world prevalence of HCV of 14.7%. Luckily, we have the first world national program treating all our patients. It will be a good opportunity to discuss with the world experts in this field the results of their researches, and the real life results of different national protocols that are currently ongoing specially in the AsiaPacific region.

By reaching the date of the congress on September 2017, there will be more than one million Egyptian patients that have been cured from the virus using the currently available DAAs. The congress will provide an excellent opportunity to share and exchange experiences especially from the view of Asian Pacific countries regarding the latest scientific and evidence-based research results and recommendations to follow-up the cured patients, to treat their damaged liver cells, to dissolve their fibrous bands, to detect and treat early any rising liver cancers. These elements are essential to pave a way for better treatment of HCV patients not only in the AsiaPacific region but among the world.

We planned to have 1 day of post-graduate educational program as well as 2 days for the core of the meeting. The core program is to provide an overview of different aspects of HCV with the State-of-the Art Lectures on hot-off-the-press issues. Free papers and poster presentations is always the soul of the conference to share research findings and there will be several awards available for application aimed to support young scientists to attend the conference and encourage scientific research. We thus enthusiastically invite all of you to submit abstract and join us in this conference.

In addition to the scientific program, an interesting social program for the doctors and their companions have been well prepared. Visiting the historical parts of old Cairo, the Coptics and the Islamic heritage as well as the pyramids, the sphinx and the old Egyptian museum will be memorial time. Luckily enough by September 2017, the outstanding new-Egyptian cultural museum will have its doors opened to show the largest collections of the era of Pharos. For those who have been prepared to have available time, it will be an outstanding chance having one of two options. Either to visit the two beauty cities in the upper Egypt, Luxur and Aswan to see the Temples, or to travel to one of the resorts or diving places in the north cost or the red sea (Hurgada and Sharm ElSheikh) that have been recognised as one of the highly ranked places for leisure.

We are waiting meeting you in Cairo, Egypt on September 6-8, 2017

Best of our Greetings


President of the Congress


Vice-President of the Congress

APASL STC on HCV Treatment - The Real Life Results in Egypt

Date: September 6-8, 2017
City: Cairo, Egypt
President: Dr. Gamal Shiha

Future APASL Conferences

APASL 2018 Annual Meeting in India

Date: March 15-18, 2018
City: New Delhi, India
President: Dr. Barjesh C. Sharma

APASL 2019 Annual Meeting in Philippines

Date: February 20-24, 2019
City: Manila, Philippines
President: Dr. Diana A. Payawal

APASL STC on HCV and Coinfection in Mongolia

Date: June 16-18, 2017
City: Ulaanbaatar, Mongolia
President: Dr. Oidov Baatarkhuu

APASL STC on HCC in Japan

Date: May 11-13, 2018
City: Yokohama, Japan
President: Dr. Shuichiro Shiina

APASL STC HBV in Asia-Pacific in Taiwan

Date: June 22-24, 2018
City: Taipei, Taiwan
President: Dr. Rong-Nan Chien

APASL STC on HCV in Malaysia

Date: 2018 (to be announced)
City: Kuala Lumpur, Malaysia
President: Dr. Rosmawati Mohamed

APASL Guidelines

Now the APASL Guidelines have been published in Hepatology International as follows!!!

APASL Guidelines for HBV (Hepatol Int (2016) 10:1–98)

*This APASL Guideline can be downloaded by clicking below.

APASL Guidelines for HCV -”APASL consensus statements and recommendation for hepatitis C prevention, epidemiology, and laboratory testing” (Hepatol Int (2016) 10:681–701)

*This APASL Guideline can be downloaded by clicking below.

APASL Guidelines for HCV -”APASL consensus statements and recommendation on treatment of hepatitis C” (Hepatol Int (2016) 10:702–726)

*This APASL Guideline can be downloaded by clicking below.

APASL Guidelines for HCC -”Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma” (Hepatol Int 2010; 4: 439-474)

*This APASL Guideline can be downloaded by clicking below.

APASL Guidelines for Acute-on-chronic Liver Failure -”Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014” (Hepatol Int 2014; 8: 453-471)

*This APASL Guideline can be downloaded by clicking below.

APASL Guidelines for Fibrosis -”Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)” (Hepatol Int 2009; 3: 323-333)

*This APASL Guideline can be downloaded by clicking below.

APASL consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis a 2016 update (Hepatol Int (2017) 11:1–30)

*This APASL Guideline can be downloaded by clicking below.

APASL Guidelines for IPH -”Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment” (Hepatol Int 2007; 1: 398-413)

*This APASL Guideline can be downloaded by clicking below.

APASL Guidelines for Variceal Bleeding -”Primary prophylaxis of gastroesophageal variceal bleeding: consensus recommendations of the Asian Pacific Association for the Study of the Liver” (Hepatol Int 2008; 2: 429-439)

*This APASL Guideline can be downloaded by clicking below.

APASL Fellowship 2017

The objective of the fellowship is to foster career development by encouraging the beneficial experience of working in a different clinical or research environment in another country in the Asia-Pacific region. These fellowships provide for advanced training in health and medical research in any country in the Asia-Pacific region and enable fellows to work in a clinical environment or on a research project with nominated advisers. We appreciate your generous contributions and support for these APASL fellowships and look forward to a number of high-quality applications for a 2017 fellowship.

An application form can be downloaded by clicking here: Please fill in and send to the APASL secretariat ( We are looking forward to receiving your application. There are no restrictions based on nationality. The sponsoring institution with the academic environment to provide adequate support for the proposed project might be suggested by APASL. Application will be reviewed by APASL Committee members. The decisions of the Committee are final and not subject to appeal.